Company news
VYNE Therapeutics Inc. news in 2020
VYNE Therapeutics Inc.'s news releases, calls and decks from 2020, newest first.
VYNE Therapeutics Reports Successful End-of-Phase 2 Meeting with the FDA for FCD105 in Acne
December 16, 2020
VYNE Therapeutics Announces New U.S. Patent Expiring in 2037 for AMZEEQ® (minocycline) topical foam, 4%
December 14, 2020
VYNE Therapeutics Announces Publication of Long-term Safety & Efficacy Data for ZILXI™ (minocycline) topical foam, 1.5% in the Journal of Clinical and Aesthetic Dermatology
November 30, 2020
VYNE Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update
November 4, 2020
VYNE Therapeutics to Report Third Quarter 2020 Financial Results on November 5th
October 27, 2020
VYNE Therapeutics Announces Covered Status for ZILXI™ (minocycline) with Express Scripts
October 6, 2020
VYNE Therapeutics Announces ZILXI™ (minocycline) topical foam, 1.5% is Available in Pharmacies Nationwide Today, October 1st
September 30, 2020
VYNE Therapeutics Announces ZILXI™ (minocycline) topical foam, 1.5% Available in Pharmacies Nationwide on October 1st
September 30, 2020
VYNE Therapeutics to Host Physician Symposium on AMZEEQ® and ZILXI™
September 22, 2020
VYNE Therapeutics Announces the Appointment of Patrick G. LePore to its Board of Directors
September 13, 2020
Calls in 2020
Decks in 2020
- Investor Presentation (September 2020)
Investor deck · 28 slides · Sep 14, 2020
- Menlo Therapeutics — Investor Presentation (June 2020)
Investor deck · 30 slides · Jun 2, 2020